List of Orfadin drug patents

Orfadin is owned by Swedish Orphan.

Orfadin contains Nitisinone.

Orfadin has a total of 1 drug patent out of which 0 drug patents have expired.

Orfadin was authorised for market use on 22 April, 2016.

Orfadin is available in suspension;oral dosage forms.

Orfadin can be used as treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine.

The generics of Orfadin are possible to be released after 28 February, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9301932 SWEDISH ORPHAN Liquid pharmaceutical composition comprising nitisinone
Feb, 2033

(10 years from now)

Drugs and Companies using NITISINONE ingredient

Market Authorisation Date: 22 April, 2016

Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Dosage: SUSPENSION;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in